Low-Dose Naltrexone Compassionate Use and Expanded Access: How to Get LDN Cheaper

Does LDN have a compassionate-use or expanded-access pathway?

Expanded access is FDA's route for patients with serious or immediately life-threatening conditions who cannot get a promising investigational medicine through a clinical trial [2]. Right to Try is a separate pathway for patients with a life-threatening disease or condition who have exhausted approved treatment options, cannot participate in a clinical trial, and give written informed consent. The drug must have completed a phase 1 trial, must not be approved by FDA for any use, must be the subject of an FDA application or an active investigational new drug application for a trial intended to support approval, and must still be in active development or production [2].

Neither route matches how LDN is supplied. Naltrexone is already FDA-approved for other uses, and no FDA-approved low-dose product exists. LDN is naltrexone prescribed well below the approved 50 mg dose and supplied mainly through compounding pharmacies rather than as an investigational product in development [1][4].

Why LDN is a compounded prescription

Naltrexone 50 mg tablets were approved on 20 November 1984 for alcohol dependence and for blockade of the effects of exogenously administered opioids; Revia is now listed as discontinued, and generics remain available [4][6]. Vivitrol, a 380 mg extended-release intramuscular injection given every four weeks, was approved on 13 April 2006 [5][7]. LDN is naltrexone at roughly 0.5 to 6 mg a day, most often 4.5 mg, used off-label for conditions such as fibromyalgia, multiple sclerosis, Crohn's disease and long COVID [1]. A 2026 narrative review calls the 4.5 mg dose empirically derived rather than evidence-based [1].

Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach patients [3][8]. FDA notes that poor compounding practices can produce contamination or a product with too much or too little active ingredient, and that compounded drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug [8].

The approved naltrexone labels cover the 50 mg tablet and the 380 mg injection and give no guidance on LDN doses. Their contraindication for people receiving opioid analgesics is written without any dose exception [4][5]. The labels also say that starting naltrexone too soon after opioid use can precipitate withdrawal severe enough to require hospitalization. They recommend a minimum of 7 to 10 opioid-free days, and the tablet label says people switching from buprenorphine or methadone may remain vulnerable for as long as 2 weeks [4][5]. The tablet label also reports that placebo-controlled studies at up to 300 mg a day showed hepatocellular injury in a substantial proportion of patients exposed to those higher doses [4].

How can a patient compare LDN cost?

Ask more than one compounding pharmacy for the price of the exact prescribed preparation, including its dose, form and quantity, and compare the same preparation at each pharmacy. A prescription written for capsules is not the same preparation as one written for a liquid, so the quote needs to match what was prescribed.

FDA also says that people who buy compounded drugs online, including through telehealth platforms, may not know which compounder produced the drug or whether it meets appropriate quality standards [8].